Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

5.46
-0.0300-0.55%
Post-market: 5.43-0.0294-0.54%19:58 EDT
Volume:2.31M
Turnover:12.73M
Market Cap:442.84M
PE:-4.37
High:5.66
Open:5.50
Low:5.38
Close:5.49
Loading ...

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Alpha Tau Medical Ltd (DRTS)

TIPRANKS
·
23 May

BRIEF-Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Reuters
·
19 May

Altimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide

TIPRANKS
·
19 May

Altimmune Inc - Impact Phase 2B Trial Topline Data Expected in Q2 2025

THOMSON REUTERS
·
19 May

Altimmune Announces Initiation of Reclaim Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

THOMSON REUTERS
·
19 May

Piper Sandler Sticks to Its Buy Rating for Altimmune (ALT)

TIPRANKS
·
14 May

Altimmune Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital

MT Newswires Live
·
13 May

BRIEF-Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital

Reuters
·
13 May

BRIEF-Altimmune Q1 Net Income USD -19.575 Million

Reuters
·
13 May

Altimmune Q1 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.00K, Same YoY, Cash And Equivalents $150M

Benzinga
·
13 May

Altimmune Q1 Revenue USD 5 Thousand VS. Ibes Estimate USD 0

THOMSON REUTERS
·
13 May

Altimmune Q1 Basic EPS USD -0.26

THOMSON REUTERS
·
13 May

Altimmune Secures up to $100 Million in Credit Facility From Hercules Capital

THOMSON REUTERS
·
13 May

Altimmune Inc - Pemvidutide Phase 2B Trial Data Expected Q2 2025

THOMSON REUTERS
·
13 May

Press Release: Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Dow Jones
·
13 May

Altimmune Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
09 May

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

THOMSON REUTERS
·
06 May

Altimmune Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
05 May

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

GlobeNewswire
·
01 May